Log in

NASDAQ:BEAT - BioTelemetry Stock Price, Forecast & News

$39.50
+2.55 (+6.90 %)
(As of 03/31/2020 03:41 AM ET)
Today's Range
$36.21
Now: $39.50
$39.62
50-Day Range
$28.93
MA: $42.90
$54.56
52-Week Range
$27.35
Now: $39.50
$63.24
Volume306,071 shs
Average Volume335,295 shs
Market Capitalization$1.35 billion
P/E Ratio48.17
Dividend YieldN/A
Beta1.43
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More
BioTelemetry logo

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$439.11 million
Cash Flow$3.60 per share
Book Value$10.83 per share

Profitability

Net Income$29.84 million

Miscellaneous

Employees1,700
Market Cap$1.35 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.


BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

How has BioTelemetry's stock been impacted by COVID-19 (Coronavirus)?

BioTelemetry's stock was trading at $37.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BEAT shares have increased by 5.2% and is now trading at $39.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioTelemetry?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioTelemetry.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for BioTelemetry.

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) issued its quarterly earnings data on Wednesday, February, 26th. The medical research company reported $0.48 EPS for the quarter, hitting the consensus estimate of $0.48. The medical research company had revenue of $112.03 million for the quarter, compared to the consensus estimate of $110.35 million. BioTelemetry had a net margin of 6.80% and a return on equity of 20.23%. View BioTelemetry's earnings history.

What price target have analysts set for BEAT?

6 brokers have issued 1-year price targets for BioTelemetry's shares. Their forecasts range from $54.00 to $80.00. On average, they expect BioTelemetry's stock price to reach $66.17 in the next year. This suggests a possible upside of 67.5% from the stock's current price. View analysts' price targets for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Media coverage about BEAT stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioTelemetry earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutBioTelemetry.

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,686,100 shares, an increase of 7.0% from the February 27th total of 2,510,000 shares. Based on an average daily trading volume, of 383,600 shares, the days-to-cover ratio is currently 7.0 days. Approximately 8.2% of the shares of the stock are sold short. View BioTelemetry's Current Options Chain.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), IMAC (IMAC), AAC (AAC) and Biocorrx (BICX).

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Square (SQ), Netflix (NFLX), Alibaba Group (BABA), ABIOMED (ABMD), Paypal (PYPL), Adobe (ADBE), Canopy Growth (CGC) and Advanced Micro Devices (AMD).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the following people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $39.50.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.35 billion and generates $439.11 million in revenue each year. The medical research company earns $29.84 million in net income (profit) each year or $1.95 on an earnings per share basis. BioTelemetry employs 1,700 workers across the globe. View additional information about BioTelemetry.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com/.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel